SI3172227T1 - Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni - Google Patents

Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni

Info

Publication number
SI3172227T1
SI3172227T1 SI201530968T SI201530968T SI3172227T1 SI 3172227 T1 SI3172227 T1 SI 3172227T1 SI 201530968 T SI201530968 T SI 201530968T SI 201530968 T SI201530968 T SI 201530968T SI 3172227 T1 SI3172227 T1 SI 3172227T1
Authority
SI
Slovenia
Prior art keywords
molecules
cells
treatment
autoimmune diseases
selectively activate
Prior art date
Application number
SI201530968T
Other languages
English (en)
Slovenian (sl)
Inventor
Jeffrey Greve
Original Assignee
Delinia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3172227(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Delinia, Inc. filed Critical Delinia, Inc.
Publication of SI3172227T1 publication Critical patent/SI3172227T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201530968T 2014-07-21 2015-07-20 Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni SI3172227T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP15824955.7A EP3172227B9 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SI3172227T1 true SI3172227T1 (sl) 2020-02-28

Family

ID=55163946

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530968T SI3172227T1 (sl) 2014-07-21 2015-07-20 Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni

Country Status (22)

Country Link
US (6) US20170037102A1 (hr)
EP (2) EP3172227B9 (hr)
JP (2) JP6768633B2 (hr)
KR (1) KR102493543B1 (hr)
CN (2) CN106795213B (hr)
AU (3) AU2015292889C1 (hr)
CA (1) CA2954847A1 (hr)
DK (1) DK3172227T3 (hr)
EA (2) EA202190903A3 (hr)
ES (1) ES2763198T3 (hr)
GB (1) GB2538666A (hr)
HU (1) HUE046065T2 (hr)
IL (3) IL289475B2 (hr)
LT (1) LT3172227T (hr)
MX (2) MX2017000821A (hr)
PL (1) PL3172227T3 (hr)
PT (1) PT3172227T (hr)
RS (1) RS59789B1 (hr)
SG (2) SG10202010158TA (hr)
SI (1) SI3172227T1 (hr)
WO (1) WO2016014428A2 (hr)
ZA (1) ZA201700344B (hr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201808463RA (en) 2012-12-11 2018-11-29 Albert Einstein College Medicine Yeshiva Univ Methods for high throughput receptor:ligand identification
EP3172227B9 (en) * 2014-07-21 2020-01-08 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
WO2018089420A1 (en) * 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
US10472405B2 (en) * 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
EP3558339B1 (en) 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
EP3604538A4 (en) 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
WO2019112854A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Il-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
JP7275049B2 (ja) 2017-12-27 2023-05-17 協和キリン株式会社 Ｉｌ－２改変体
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
CN112154153A (zh) 2018-03-28 2020-12-29 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
EP3552738B1 (en) * 2018-04-12 2024-07-31 Sandvik Machining Solutions AB A method of producing an additive manufactured object
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
CA3108865A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3875475A4 (en) * 2018-12-21 2022-12-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. VARIANT OF HUMAN INTERLEUKIN-2 OR ITS DERIVATIVE
AU2020214812A1 (en) 2019-02-01 2021-09-23 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
EA202192146A1 (ru) 2019-02-15 2021-11-09 Интиграл Молекьюлар, Инк. Антитела к клаудину 6 и их применение
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
JP2022544771A (ja) * 2019-08-12 2022-10-21 アスクジーン・ファーマ・インコーポレイテッド 優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質
JP7427287B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物
US11718654B2 (en) 2019-11-05 2023-08-08 Medikine, Inc. IL-2R-βγ binding compounds
BR112022011414A2 (pt) 2019-12-12 2022-08-30 Iltoo Pharma Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
WO2021127487A2 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
TW202417475A (zh) 2020-02-03 2024-05-01 美商麥地金公司 IL-7Rα結合化合物
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
KR20230009872A (ko) 2020-05-12 2023-01-17 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
GB2621482A (en) 2020-05-13 2024-02-14 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
AU2021364387A1 (en) 2020-10-23 2023-06-15 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
MX2023005458A (es) 2020-11-13 2023-05-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que comprende una variante de la interleucina humana 2 o un derivado de la misma y uso de la misma.
MX2023010926A (es) * 2021-03-31 2023-09-27 Hanmi Pharmaceutical Co Ltd Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo.
BR112023020597A2 (pt) 2021-04-09 2023-12-12 Selecta Biosciences Inc Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
CN100390282C (zh) * 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
EP1641823B1 (en) 2003-06-12 2011-09-21 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2005012530A2 (en) * 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
PL2066694T3 (pl) * 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP2382228B1 (en) * 2009-01-21 2020-08-26 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
ES2572728T3 (es) * 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
PT2542590T (pt) * 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
RS62238B1 (sr) * 2011-02-10 2021-09-30 Roche Glycart Ag Mutantni interleukin-2 polipeptidi
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
EP3172227B9 (en) * 2014-07-21 2020-01-08 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
US20220112260A1 (en) 2022-04-14
EA202190903A3 (ru) 2021-12-31
DK3172227T3 (da) 2019-12-02
GB201615553D0 (en) 2016-10-26
GB2538666A (en) 2016-11-23
US20210047382A1 (en) 2021-02-18
WO2016014428A3 (en) 2016-03-24
US20170327555A1 (en) 2017-11-16
EA201790213A1 (ru) 2017-06-30
JP6768633B2 (ja) 2020-10-14
IL289475B1 (en) 2023-06-01
CA2954847A1 (en) 2016-01-28
EP3587444A1 (en) 2020-01-01
EP3172227B1 (en) 2019-09-04
HUE046065T2 (hu) 2020-01-28
AU2015292889B2 (en) 2020-02-27
US20170037102A1 (en) 2017-02-09
WO2016014428A2 (en) 2016-01-28
PT3172227T (pt) 2019-12-06
IL250024A0 (en) 2017-03-30
SG10202010158TA (en) 2020-11-27
CN114133456A (zh) 2022-03-04
ES2763198T3 (es) 2020-05-27
AU2022204946A1 (en) 2022-07-28
RS59789B1 (sr) 2020-02-28
KR20170028938A (ko) 2017-03-14
EP3172227B9 (en) 2020-01-08
LT3172227T (lt) 2020-02-10
IL289475A (en) 2022-02-01
US20190375812A1 (en) 2019-12-12
CN106795213B (zh) 2021-12-07
MX2021000083A (es) 2021-03-25
SG11201700514SA (en) 2017-02-27
KR102493543B1 (ko) 2023-01-30
IL289475B2 (en) 2023-10-01
EP3172227A4 (en) 2017-12-20
MX2017000821A (es) 2017-08-18
AU2015292889C1 (en) 2023-01-19
EA038361B1 (ru) 2021-08-13
EP3172227A2 (en) 2017-05-31
CN106795213A (zh) 2017-05-31
JP2021006038A (ja) 2021-01-21
ZA201700344B (en) 2020-08-26
IL250024B (en) 2020-11-30
US20170051029A1 (en) 2017-02-23
IL278299B (en) 2022-02-01
PL3172227T3 (pl) 2020-04-30
JP2017527272A (ja) 2017-09-21
EA202190903A2 (ru) 2021-07-30

Similar Documents

Publication Publication Date Title
IL289475A (en) Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases
ZA201804458B (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HK1243001A1 (zh) 選擇性地活化調節性t細胞用於治療自身免疫病的修飾的il-2變體
HK1245827B (zh) 受控激活或消除治療性細胞的方法
IL249065A0 (en) Combination of treatments for cancer treatment
EP3227330C0 (en) TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
RS61536B1 (sr) Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
IL249710A0 (en) Wastewater treatment system
PL3012014T3 (pl) Instalacja obróbki płynu
GB201414023D0 (en) Treatment of autoimmune diseases
GB201412441D0 (en) Treatment system
ZA201403183B (en) Effluent treatment system